Remimazolam

Overview

Remimazolam is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4297526).

API suppliers (1)

Suppliers of Remimazolam evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• PAION UK LTDGermany1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Remimazolam expires 13 Jan 2034. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate

Canonical SMILES

CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4

InChIKey

CYHWMBVXXDIZNZ-KRWDZBQOSA-N